Stocks · News reference
Syndax Pharmaceuticals announced that its FDA-approved menin inhibitor, Revuforj (revumenib), received the 2026 Best Product for Rare/Orphan Diseases award from The Galien Foundation.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Syndax Pharmaceuticals has received notification that 19 abstracts regarding its pipeline therapies, Revuforj and Niktimvo, have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting.
Syndax Pharmaceuticals announced the grant of stock options to five new employees as an inducement for their employment.
Syndax Pharmaceuticals will host an in-person investor event and live webcast on December 14, 2026, during the ASH Annual Meeting.
HC Wainwright & Co. has maintained its 'Buy' rating on Syndax Pharmaceuticals while adjusting the 12-month price target from $38 to $36.
Syndax Pharmaceuticals reported total revenue of $83.3 million for the third quarter of 2026, exceeding analyst expectations.